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Introduction: Transcription factor p53 has a powerful tumor suppressing function that is 
associated with many cancers. Since the molecular weight of p53 is 53 kDa, it is difficult to 
transport across cell membranes. Thymidine dinucleotide (pTT) is an oligonucleotide that can 
activate the p53 transcription factor and trigger the signal transduction cascade. However, the 
negative charge and high water solubility of pTT limit its transport through cellular membranes, 
thereby preventing it from reaching its target in the nucleus. A suitable delivery carrier for pTT 
is currently not available.
Objective: The purpose of this study was to employ a nanoscale liposomal carrier to resolve 
the delivery problem, and increase the bioavailability and efficiency of pTT.
Methodology: The approach was to employ liposomes to deliver pTT and then evaluate the 
particle size and zeta potential by laser light scattering (LLS), and permeation properties of 
pTT in vitro in a Franz diffusion assembly, and in vivo in a murine model using confocal laser 
scanning microscopy (CLSM).
Results: We found that dioleoylphosphatidylethanolamine (DOPE) combined with   cholesterol 
3 sulfate (C3S) were the best ingredients to achieve an average desired vehicle size of 
133.6 ± 2.8 nm, a polydispersity index (PDI, representing the distribution of particle sizes) 
of 0.437, and a zeta potential of −93.3 ± 1.88. An in vitro penetration study showed that the 
liposomal carrier was superior to the free form of pTT at 2–24 hours. CLSM study observed 
that the penetration depth of pTT reached the upper epidermis and potential of penetration 
maintained up to 24 hours.
Conclusion: These preliminary data demonstrate that nanosized DOPE/C3S liposomes can be 
exploited as a potential carrier of drugs for topical use in treating skin diseases.
Keywords: thymidine dinucleotide, p53, liposome, permeation ability, confocal laser scanning 
microscopy
Introduction
The p53 tumor suppressor gene is well known and provides a major anticancer 
defense mechanism. Almost 80% of human cancers are associated with mutations 
of the p53 gene, which selectively delete or silence p53, thus promoting tumor pro-
gression and metastasis.1,2 Normally, there are two classes of genes: oncogenes and 
tumor suppressor genes. One composed of oncogenes which cause the cell to divide 
in an unregulated manner when a single altered copy leads to mutation, and another 
composed of antion-cogenes which provide a protection mechanism, also called a 
tumor-suppressor gene. Autoregulatory feedback mechanisms exist to achieve a balance 
between oncogenes and anti-oncogenes. In brief, the p53 gene acts as a regulator of 
anti-oncogenes or as a tumor suppressor due to its ability to maintain normal growth International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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control and genomic stability.3 Recent work showed that p53 
is activated by multiple pathways, such as DNA damage, and 
oncogenic and oxidative stress; so different stress signals can 
mediate different signaling pathways.4
Several skin cancers, including basal cell carcinoma 
(BCC) and squamous cell carcinoma (SCC), are also related 
to p53 mutations, and the site of the mutation is the basis 
for distinguishing skin cancers.5,6 Skin cancer induced by 
ultraviolet (UV) radiation may trigger apoptosis in a p53-
dependent manner and the formation of sunburned cells 
(apoptotic keratinocytes). Numerous studies also indicated 
that triggering p53 induction inactivates the division of 
  cancer cells.7,8 Thymidine dinucleotide (pTT), a fragment of 
an oligonucleotide, activates the p53 transcription factor and 
p53 protein, and triggers a cascade of DNA-repair enzymes 
according to in vitro and in vivo evidence which focuses 
on UV radiation-induced mutagenesis and carcinogenesis.9 
Typically, oligonucleotides have a high molecular weight, a 
negative charge, and high water solubility, which causes prob-
lems when transporting them through cellular membranes to 
generate specific reactions in nuclei.10 According to the above 
data, the bioavailability of pTT is low when it is delivered 
through cellular membranes by passive diffusion.
Drug delivery systems were therefore designed to 
  protect nucleic acids from being destroyed in environmental 
  conditions and allow them to enter skin cells and reach the 
site of action. In designing formulation systems, biocompat-
ibility is one of the most important considerations.   Previous 
  studies employed a mixed solution of 75% propylene 
glycol and 25% dimethyl sulfoxide (DMSO) to deliver a 
biologically active concentration of pTT to guinea pig skin, 
and despite its effectiveness, it did cause skin damage.11,12 
Biocompatibility and safety must be considered to make 
such solutions feasible in clinical applications. Liposome 
systems are exploited as biocompatible delivery vesicles for 
both systemic and topical administration in clinical usage. 
Liposomal delivery systems can enhance the permeability 
of hydrophilic drugs and localize them to target tissues.13 
Moreover, phospholipids are nontoxic and biodegradable, 
and prolong the half-life of drugs to attain a sustained-release 
effect. Previous studies demonstrated that phospholipids 
exhibit their enhancing effect on the application of topical 
delivery.14–16 Phospholipids are recognized to have skin 
permeation enhancing ability.
The aim of this study was to improve the bioavailability 
of the nucleotide fragment, thymidine dinucleotide (pTT), 
using liposomal carriers to deliver the drug into the skin, and 
we focused our investigation on the skin permeation behavior. 
The applicability of liposomal carriers was demonstrated 
through extensive characterization of the particle size and 
zeta potential, and by transmission electron microscopic 
(TEM) studies. The cellular viability was evaluated using 
skin fibroblast and keratinocyte cell lines. Moreover, the skin 
delivery and penetration behavior of pTT-loaded liposomes 
were investigated by in vitro Franz diffusion cell and in vivo 
confocal laser scanning microscopy (CLSM).
Materials and methods
Materials
pTT with or without 5′ fluorescein was obtained from Protech 
Technology (Taipei, Taiwan). 1,2-Dioleoyl-sn-glycero-
3-phosphoethanolamine (DOPE, with a purity of .95%) 
was purchased from Avanti Polar Lipids (Alabaster, AL). 
Cholesterol-3-sulfate (C3S) was purchased from Sigma 
Chemical (St Louis, MO). Other chemicals used in the study 
were of reagent grade.
Preparation of liposomes
Liposomes were prepared according to the thin-film   hydration 
method. DOPE and C3S were dissolved in 5 mL of a 
chloroform:methanol (2:1, v/v) solution in round-bottomed 
flasks. Organic solvent traces were evaporated by a rotary 
evaporator above the transition temperature of the lipid, and 
solvent traces were removed under a vacuum overnight. The 
thin film was fully hydrated with double-distilled water contain-
ing pTT at 100 µmol/L for 20 minutes. The vesicle suspension 
was dispersed by a probe-type sonicator (VCX 600; Sonics and 
Materials, Newtown, CT) at 25 W for 10 minutes.
Vesicle size and zeta potential
The vesicle size and zeta potential of the liposomes 
were   measured by laser light scattering (LLS) with a 
helium-neon laser at 630 nm (Nano ZS1 90; Malvern, 
Worcestershire, UK). Liposomal suspensions were directly 
measured. The   polydispersity index (PDI) was used to mea-
sure the size distribution. All vesicle sizes and zeta potentials 
were   measured at 25°C. Measurements were repeated three 
times per sample for three samples.
Morphology observation by TeM
The liposomal vesicles were examined by TEM to 
  characterize their microstructure. A drop of liposomes was 
applied to a carbon film-covered copper grid to form a thin-
film specimen, which was stained with 1% phosphotungstic 
acid. The sample was then examined and photographed with 
a Jeol JEM-1230 TEM (Jeol Ltd, Tokyo, Japan).International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
3375
Topical delivery of thymidine dinucleotide from liposomes
Quantification of pTT-fluorescein
The pTT-fluorescein standard was determined spectrofluo-
rometrically (Hitachi F-2500; Hitachi, Tokyo, Japan) at an 
excitation wavelength of 494 nm and emission at 519 nm. The 
calibration curve exhibited good linearity (r = 0.97).
cellular viability
Cellular viability was used to determine the percentage 
cell survival by a 3,(4,5-dimethylthiazol-2-yl)2,5-diphenyl-
tetrazoleum bromide (MTT) assay, which produces formazan 
crystals in mitochondria within cells. A fibroblast cell line 
(Hs68) and keratinocyte (HaCat) cells were seeded on 96-well 
plates at a cell density of 5 × 103 cells/well until cells were 
confluent. Dulbecco’s modified Eagle’s medium (DMEM) 
was replaced by liposomal suspensions for 12 and 24 hours at 
37°C in air containing 5% CO2. We then added 50 µL of the 
MTT solution (50 µg/mL) to each well and incubated the wells 
for 4 hours. In order to dissolve the water-insoluble formazan, 
MTT/medium was removed from each well, and 100 µL of 
dimethyl sulfoxide (DMSO) was added to each one. The 
extent of cell survival was determined by an enzyme-linked 
immunosorbent assay (ELISA) reader at 550 nm.
In vitro evaluation of the skin  
penetration ability
We measured the topical delivery of pTT-fluorescein using 
a modified Franz vertical diffusion assembly (Ching Fa, 
HsinChu, Taiwan). Normal nude mouse skin was used as the 
barrier membrane. The donor medium consisted of 0.5 mL of 
a pTT-fluorescein liposomal formulation or control solution 
(pTT-fluorescein in distilled water), and the receptor medium 
consisted of 5.5 mL of pH 7.4 citrate-phosphate buffer. The 
available diffusion area was 0.785 cm2. The stirring rate of 
the receptor was 600 rpm, and the temperature was main-
tained at 37°C. At appropriate intervals, 200 µL aliquots 
of the receptor medium were withdrawn and immediately 
replaced by an equal volume of fresh buffer. The concen-
tration of pTT-fluorescein was measured by a fluorescence 
spectrometer (F-2500, Hitachi, Tokyo, Japan) at λexcitation of 
494 nm and λemission of 519 nm. The cumulative amount of 
pTT-fluorescein was examined at the end of the in vitro 
experiments (24 hours) (n = 4).
In vivo topical delivery  
of the liposomal carriers
A glass cylinder with an available area of 0.785 cm2 was placed 
with glue on the dorsal skin of a mouse. pTT-fluorescein that was 
or was not encapsulated in a   liposomal formulation (100 µL) 
was added to each cylinder for 2, 4, 6, and 24 hours. At the end 
of the incubation period, the formulation was removed, and the 
skin was wiped ten times with a cotton cloth. The amount of 
pTT-fluorescein retained in the skin was measured by confocal 
laser scanning   microscopy (CLSM). All procedures were carried 
out in the dark to prevent the influence of ambient light.
evaluation of the penetration  
behavior by cLsM
CLSM was used to scan the pTT-fluorescein signal at differ-
ent skin depths. The excised nude mouse skin was positioned 
on the microscopic slide with the stratum corneum (SC) side 
facing the cover glass. The CLSM Leica TCS SP2 confocal 
microscope (Leica Microsystems, Wetzlar, Germany) was used 
with an argon laser beam, excitation at 488 nm, and emission 
at 543 nm. Each skin sample was sliced in sections of 6–10 µm 
thick through the z-axis by CLSM. The pTT-fluorescein inten-
sity and the permeated depth were detected by CLSM with 
Leica Confocal Software version 2.61 (Leica Microsystems, 
Wetzlar, Germany). Since CLSM was not able to be calibrated, 
we used arbitrary units to compare the data.
statistical analysis
Data are expressed as the mean ± SD. Statistical analyses were 
performed using unpaired Student’s t-test with WINKS 6.0 
software (Texasoft, TX). A 0.05 level of probability was used 
as the level of significance. Analysis of variance (ANOVA) 
was also used.
Results and discussion
The oligonucleotide fragment pTT can activate the p53 
transcription factor and trigger tumor suppressor function. 
However, the negative charge and high water solubility of 
pTT limits its transport through cellular membranes and 
its ability to reach its target sites. Improving the poor bio-
availability of pTT is necessary to proceed with the clinical 
investigations. The present study demonstrates that topical 
delivery of pTT using liposomal carriers can successfully 
resolve the delivery problem. We established the properties 
of pTT-loaded liposomes and their permeability behavior in 
in vitro and in vivo models. CLSM study observed that the 
effect on skin reached the upper epidermis.
characterization of pTT-loaded 
liposomes
The particle size, PDI, and zeta potential of the liposomes 
with and without pTT were measured by an LLS system, 
and the results are shown in Table 1. We observed no International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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  distinct, undissolved crystals in the liposomal mixtures. 
The morphology of DOPE liposomes with pTT was also 
shown under TEM observations (Figure 1). DOPE lipo-
somal vesicles were spherical. Moreover, results of the 
PDI were 0.39–0.44, which represent the well distribution 
of particle sizes. The composition with DOPE and C3S at 
a molar ratio 2.68 achieved the best condition. Liposome 
vesicles with or without pTT incorporation had particle 
sizes of 123 and 36 nm, respectively. Liposomes incor-
porating pTT were clearly larger than those without pTT 
(P , 0.05).
The skin penetration behavior was strongly dependent on 
the formulation characteristics. In our cases, diameters of 
the liposomal particles were controlled to ,40 and 120 nm 
in empty and pTT-loaded liposomes, respectively. Generally, 
egg phosphatidylcholine (EPC) was used as phospholipid 
in the preparation of traditional liposome, the head group 
of phospholipid structure with choline N+(CH3)3 group. In 
this case, we chose phosphatidylethanolamine (PE) as the 
main phospholipid materials, with NH3+ as the head of the 
group. Past evidences pointed out that liposomes composed 
of EPC were significantly larger than those composed of PE 
in terms of particle size.17 This phenomenon was the same 
in our case. The PE type of phospholipid can form smaller 
particle sizes when incorporated with another surfactant in 
a proper ratio which is mainly related to the properties of 
PE. In addition, PE is a phospholipid which exhibits a high 
tendency to form the inverted hexagonal phase, particularly 
at an acidic pH.18 Protonation of the head group of PE, 
caused by a reduction of the pH in physiological conditions, 
neutralizes the negative charge, and the vesicles become 
destabilized as the PE component reverts to the hexagonal 
phase.19 Moreover, the zeta potentials of empty liposomes 
and pTT-loaded liposomes were about −63.17 ± 4.11 and 
−93.3 ± 1.88 mV, respectively. When pTT was loaded in 
liposomes the negative charge significantly increased, which 
was mainly attributed to pTT. The liposome charge plays 
a particular role in skin penetration, as discussed in the 
following section.
safety assessment
To apply liposomes as a pTT delivery carrier targeting the 
skin, acceptable toxicological properties should be assessed. 
We screened skin-associated cell lines including fibroblast 
and keratinocyte cells by using MTT assay. As shown in 
Figure 2, liposomes were examined compared to a negative 
control (pTT dissolved in double-distilled water) and a posi-
tive control (pTT dissolved in DMSO/PG: 7:3). There was 
no significant difference when liposomes were compared to 
the negative control group in fibroblast and keratinocyte cells 
(P . 0.05). Moreover, empty liposomes without pTT were 
also tested, and it was found that the vesicles themselves 
had no effect on cytotoxicity in the Hs68 cell line (P . 0.05; 
data not shown).
Past research attempted to utilize many approaches to 
transfer oligonucleotides into the skin. These approaches 
Figure 1 Transmission electron microscopic micrograph of liposomes. (Original 
magnification × 70 K).
Table 1 Physicochemical characteristics of liposomes with or without encapsulated pTT- fluorescein
Particle size (d.nm) PDI Zeta potential (mV)
DOPe/cholesterol-3-sulfate 
(molar ratio = 2.68) empty
36.73 ± 0.61 0.39 ± 0.02 −63.17 ± 4.11
DOPe/cholesterol-3-sulfate 
(molar ratio = 2.68)+pTT- fluorescein
123.33 ± 3.91 0.44 ± 0.06 −93.3 ± 1.88
Note: Data are presented as the mean ± sD (n = 3).
Abbreviations: PDI, polydispersity index; DOPe, dioleoylphosphatidylethanolamine; sD, standard deviation.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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included topical application, iontophoresis, electropo-
ration, sonophoresis, laser, microdermabrasion, and   
gene guns.20–22 The results were effective and appeared 
  promising for clinical application. Although the delivery 
efficiency showed improvement, some methods caused skin 
  irritation.23 In the present study, we selected liposomes as 
the carrier for topical delivery. Liposomes were suggested 
to be suitable carriers for topical delivery since they are 
made with the same type of lipids as those present in the 
SC, and also the materials they are composed of are safe. 
In addition, the surfactants used to prepare the liposomes 
(most often phospholipids) are similar to those contained 
in the skin; liposomes easily mix with intercellular lipids of 
the SC. Phospholipids are not toxic; their incorporation in 
the SC layer changes the composition of the lipid mixture 
and may alter the permeability of the skin. Previous studies 
suggested the excellent ability of PE to facilitate drug or 
gene delivery into cells.24,25 In addition, some cases sug-
gested that PE is easier to transfer across membranes of 
mammalian cells than phosphatidylcholine (PC) is.26
skin delivery ability by in vitro  
Franz diffusion penetration
Skin, the outermost superficial organ of the body, is an 
attractive target site for delivering/transferring drugs, active 
ingredients, and gene fragments. We evaluated the skin 
penetration ability of liposomal carriers to deliver pTT. The 
cumulative amounts (CAs) and flux of penetration were cal-
culated from the slope after plotting the accumulated amount 
of pTT from each formulation as a function of time, as shown 
in Figure 3 and Table 2. The CA tendency decreased in the 
order of positive control . liposomes . negative control. 
Moreover, the CAs between the control group (consisting of a 
pTT aqueous solution) and liposomal carriers in nude mouse 
skin significantly differed (P , 0.05). In addition, significant 
improvements in pTT delivery in terms of the CA and flux 
were about 2.67- and 2.79-fold, respectively.
We also used a mathematical simulation to predict and 
more deeply understand the kinetics of the penetration mode. 
The model that best fitted the penetration data was selected 
based on the correlation coefficient (r) value in various 
models. Zero order was the (r) value between accumulative 
amounts versus time. First order was the (r) value between 
natural logarithm of accumulative amounts versus time. Higu-
chi mode was the (r) value between accumulative amounts 
versus square root of time. The in vitro penetration study found 
that pTT dissolved in the negative control solution still had 
low cumulative amounts which penetrated into the receptor 
compartment. This indicates that hydrophilic molecules may 
penetrate into hydrophobic skin in this case because their 
molecular weight was ,500 kDa.27 However, the cumulative 
amounts did not greatly increase until 24 hours compared to 
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liposomes or the positive control group. The skin penetration 
model in the negative control group best fit the Higuchi order. 
The original data also showed a less-precise trend of the first 
and zero orders, for which the relative coefficients were 0.9325 
and 0.9201, respectively. Accordingly, for pTT dissolved in 
the control solution, the penetration pattern followed Higuchi 
kinetics which means that the pTT concentration remaining in 
the receptor compartment within a period of time is limited 
due to the saturation capacity.
The positive control group presented high enhancement 
ratios in CAs and fluxes of about 4.98- and 4.21-fold com-
pared to the negative control group; moreover, the penetration 
kinetics were also zero order. We divided the kinetics into 
two stages to discuss the kinetic modes. The initial state was 
from a period of 0–12 hours, in which pTT exhibited burst 
penetration; in the following period of 12–24 hours, it gradu-
ally achieved a steady-state. This indicates that the positive 
control group was saturated in the terminal period. On the 
other hand, in our case, enhancement ratios of CAs and flux 
in the first 24 hours were higher than those of the negative 
control group by about 2.67- and 2.79-fold. Moreover, the 
liposome system fit a zero order penetration model. Actually, 
the ideal delivery of drugs should follow zero order kinetics, 
wherein body circulation levels of drugs remain constant 
throughout the delivery period.
skin penetration behavior by in vivo 
cLsM localization
We employed an in vivo CLSM technique to observe where 
pTT was localized in order to confirm and establish the true 
potential of the carrier. CLSM profiles were acquired after 
in vivo topical administration of the negative control, posi-
tive control, and liposomes on the back skin of nude mice 
for 24 hours. CLSM images suggested the accumulation, 
distribution, and skin penetration depth of pTT, as shown in 
Figure 4. The skin thickness was optically scanned at 10 µm 
increments for nine fragments from the surface of the skin 
(left to right). A cumulative xyz image was merged of all 
optical sections. A profile of skin depth versus fluorescence 
intensity was directly obtained from the Leica Confocal 
software. Accumulation of pTT-fluorescein localization was 
presented by time course after the in vivo topical adminis-
tration for 2, 4, 6, and 24 hours (as shown in Figure 5A). 
According to the quantification data, all optical sections 
were merged, and the total intensities of pTT-fluorescein 
in nude mice skin (as shown in Figure 5B).
Table 2 In vitro permeation flux and cumulative amount of pTT across murine skin with negative control, positive control, and 
liposome treatment for 24 hours
Flux (0–24 h) Cumulative amount (CA) 
(ng/cm2)
ER (CA) ER (flux)
Negative control   5.11 ± 1.13 114.17 ± 15.70 – –
Positive control 21.97 ± 7.75 480.97 ± 172.04 4.21 4.98
Liposome 12.31 ± 1.63 304.38 ± 35.00 2.67 2.79
Note: Data are presented as the mean ± sD (n = 4).
Abbreviations: er (the enhancement ratio) = (flux or CA of the liposome or positive control group/cumulative amount of the negative group).
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The negative control group seemed to present few 
penetration trends after long-term application. The posi-
tive control group with in vivo application showed a great 
penetration flux of pTT, particularly after being applied for 
4 hours; however, as the application time increased, the pTT 
intensity dramatically decreased. It tended to respond as the 
in vitro penetration study, and we assumed that was due to a 
saturation effect of the positive control vehicle. DMSO and 
PG are well known as potential penetration enhancers by 
affecting the intracellular lipids or the intracellular proteins 
of skin structure; hence, increasing the partitioning of the 
drug into stratum corneum. In our case, we truly observed an 
enhancing effect; but it only had a short-term influence. The 
phenomena assumed relevant with pTT rapid release from 
vehicle. Past studies pointed out that DMSO is a powerful 
penetration enhancer with rapid effects in both hydrophilic 
and lipophilic compounds.28 Caspers and his group indicated 
that DMSO remained within the tissue about 4 hours and 
a small fraction was detected for days, decreasing steadily 
with time by CLSM detection.29 In this case, DMSO has 
significantly effects in promoting permeation, however in 
the limitation period.
The liposome group with in vivo application also showed 
significantly increased pTT intensity, and the initial release 
of pTT from liposomes was low followed by sustained 
release from the carrier. We assumed that since the lipo-
somal carrier was a mixture, we could not separate the 
entrapped and free drug parts in the experiment. From our 
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past evidence, phospholipid materials can assist hydrophilic 
ingredients penetrate across the skin in some circumstances.30 
  Additionally, active pharmaceutical ingredients and their 
polymorphic forms, crystallinity, particle size, solubility, 
and pharmaceutical dosage form can influence the release 
and penetration behaviors.31
The results suggested that liposome particle sizes and 
physicochemical properties play particular roles in influ-
encing pTT penetration into hydrophobic skin. The positive 
results could be expected, and were contributed by the small 
particle size and the lipophilic property which are well known 
from past evidence. Moreover, Carrer and his group pointed 
out that the presence of a negative charge in membranes of 
liposomes may allow for a better efficiency of penetration.32 
The better penetration behavior was contributed by the lipid 
layer of the SC which contains a high ratio of negatively 
charged lipids. It is well known that the skin can act as a 
negatively charged membrane.33 Pharmaceutical formula-
tions that most significantly improve drug absorption are 
made with soft (liquid) particles rather than with solid 
particles. Liposomes are themselves broken at the surface 
of skin and penetrate skin as free molecules together with 
the drug. As mentioned above, it is widely accepted that the 
skin penetration of organic particles is strongly dependent 
on particle sizes.34
Additionally, the pTT-loaded liposomes showed a highly 
negative surface charge of about –93.3 ± 1.88 mV , which 
would be related to the penetration behavior. Regarding the 
properties of the skin, the lipid layer in the SC contains a high 
ratio of negatively charged lipids, and it is well known that 
the skin can act as a negatively charged membrane.35 In addi-
tion, several researchers reported that drug penetration can be 
influenced by modifying the surface charges of liposomes.36 
Negatively charged vesicles generally produce a higher flux 
than their positively charge counterparts, which in turn can 
improve drug accumulation in the superficial skin strata.33
In terms of the skin barrier, negatively charged and hydro-
philic oligonucleotides cannot penetrate into the skin by pas-
sive diffusion. Hence, in order to become a useful therapeutic 
agent, effective delivery systems are required. Nanometer-
size systems have garnered attention for delivering genes, 
antisense oligonucleotides, and small interfering RNA in 
recent years.10 In particular, vesicle size has a great influence 
on topical drug delivery systems; vesicles of ,300 nm are 
able to deliver their contents into deeper layers of the skin 
to some extent.37,38 In the cases of liposomes with average 
diameters of ,130 nm, there is the potential for delivery 
through the skin.39 In fact, particle sizes of between 100 nm 
and 1 µm are not nanoparticles, but are correctly defined 
as submicron particles which are no longer regarded as 
“  suspect” (possibly hazardous).34 Hence, longer-term danger 
should not occur in that case.
Conclusions
Choosing a suitable vehicle is one of the key factors in devel-
oping pharmaceutics and shortening the gap to proceeding 
with clinical applications. Past evidence showed that topical 
application enhanced the DNA repair capacity and protected 
skin from the carcinogenesis risk of solar UV irradiation by 
activating the tumor suppressor gene, p53. New insights bring 
an alternative strategy to reduce/protect against skin cancer 
risks. Formulating the drug dosage and establishing the car-
rier activity and permeation parameters are part of the final 
stage of progression to clinical use. Our study contributes to 
knowledge of the delivery system to increase actual applica-
tions and confirm the safety and utility of the carriers.
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